Drug resistant tuberculosis in Italy through a global health lens.

IF 1.5 4区 医学 Q4 MICROBIOLOGY New Microbiologica Pub Date : 2023-05-01
Federico Fama, Camilla Genovese, Mario Raviglione, Andrea Gori
{"title":"Drug resistant tuberculosis in Italy through a global health lens.","authors":"Federico Fama,&nbsp;Camilla Genovese,&nbsp;Mario Raviglione,&nbsp;Andrea Gori","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-resistant tuberculosis (DR-TB) is a major global health challenge. In 2021, about one third of DR-TB patients worldwide were enrolled in treatment. In order to reach the targets set during by the 2018 UN General Assembly (UNGA) Political Declaration on Tuberculosis, a global effort must be made by both high- and low-incidence countries. Data concerning high-incidence countries are vast in the literature, but insufficient political attention has been paid in low-incidence countries to face this infectious threat. This review aims at providing an overview of DR-TB focused on different facets of DR-TB management. First, global and Italian data on the main at-risk populations for TB and DR-TB were gathered, together with the latest studies on the correlation between TB risk factors and the onset of drug resistance. Second, this review provides an analysis of obsolete Italian guidelines on the diagnosis and management of TB and DR-TB, highlighting the challenges that our country is currently facing to properly implement the latest international recommendations. Finally, some key suggestions are provided to design public health (PH) policies that can effectively tackle the DR-TB issue from a \"global health\" perspective.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 2","pages":"120-132"},"PeriodicalIF":1.5000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Microbiologica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug-resistant tuberculosis (DR-TB) is a major global health challenge. In 2021, about one third of DR-TB patients worldwide were enrolled in treatment. In order to reach the targets set during by the 2018 UN General Assembly (UNGA) Political Declaration on Tuberculosis, a global effort must be made by both high- and low-incidence countries. Data concerning high-incidence countries are vast in the literature, but insufficient political attention has been paid in low-incidence countries to face this infectious threat. This review aims at providing an overview of DR-TB focused on different facets of DR-TB management. First, global and Italian data on the main at-risk populations for TB and DR-TB were gathered, together with the latest studies on the correlation between TB risk factors and the onset of drug resistance. Second, this review provides an analysis of obsolete Italian guidelines on the diagnosis and management of TB and DR-TB, highlighting the challenges that our country is currently facing to properly implement the latest international recommendations. Finally, some key suggestions are provided to design public health (PH) policies that can effectively tackle the DR-TB issue from a "global health" perspective.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从全球健康角度看意大利的耐药结核病。
耐药结核病(DR-TB)是一项重大的全球卫生挑战。2021年,全世界约有三分之一的耐药结核病患者接受了治疗。为了实现2018年联合国大会《关于结核病问题的政治宣言》中确定的目标,高发病率国家和低发病率国家都必须作出全球努力。文献中有大量关于高发病率国家的数据,但在低发病率国家,对这一传染性威胁的政治关注不够。这篇综述的目的是提供耐药结核病的概述,重点是耐药结核病管理的不同方面。首先,收集了关于结核病和耐药结核病主要危险人群的全球和意大利数据,以及关于结核病危险因素与耐药性发生之间相关性的最新研究。其次,本综述对过时的意大利结核病和耐药结核病诊断和管理指南进行了分析,突出了我国目前在正确实施最新国际建议方面面临的挑战。最后,从“全球卫生”的角度出发,为制定有效应对耐药结核病问题的公共卫生政策提供了一些关键建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
New Microbiologica
New Microbiologica 生物-微生物学
CiteScore
2.20
自引率
5.60%
发文量
40
审稿时长
6-12 weeks
期刊介绍: The publication, diffusion and furtherance of research and study on all aspects of basic and clinical Microbiology and related fields are the chief aims of the journal.
期刊最新文献
Analysis of infection indicators and risk factors for influenza A after the COVID-19 pandemic. Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies. Comparison between rapid and laboratory serological tests in the context of the first responders during the SARS-CoV-2 outbreak: are the two tests interchangeable? Critical insights into the ocular surface microbiome: the need to standardize. Epidemiological characteristics and related risk factors of mixed infection in children with mycoplasma pneumoniae pneumonia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1